Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386723 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL3055898 | 0.76 | KDM4E (0.45) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL7412080 | 0.76 | ALDH1A1 (0.48) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL7726806 | 0.73 | CDC25A (0.51) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL21561768 | 0.70 | ALDH1A1 (0.56) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6326783 | 0.69 | ALDH1A1 (0.55) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL11602909 | 0.66 | CDK4 (0.61) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL31060923 | 0.65 | PTPRC (0.44) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL577974 | 0.64 | KDM4E (0.44) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| Benzocarbazoledione SCHEMBL22541347 | 0.64 | MAOA (0.54) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576548-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | Bayer Intellectual Property GmbH (DE) | 2013-04-10 | — | — | EP | claimed |
| EP-2170880-B1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF TETRACYCLIC COMPOUNDS | RANBAXY LAB LTD (IN) | 2012-08-15 | — | — | EP | claimed |
| WO-2011147810-A1 | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | WO | claimed |
| EP-2170880-A2 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF TETRACYCLIC COMPOUNDS | Ranbaxy Laboratories Limited (IN) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004557-A2 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF TETRACYCLIC COMPOUNDS | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | WO | claimed |
| EP-1363628-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2003-11-26 | — | — | EP | claimed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | claimed |
| WO-2002011706-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | claimed |
| EP-4065119-B1 | INITIAL TRIPLE COMBINATION THERAPY WITH MACITENTAN, TADALAFIL, AND SELEXIPAG FOR TREATING PULMONARY ARTERIAL HYPERTENSION | ACTELION PHARMACEUTICALS LTD (CH) | 2024-09-04 | — | — | EP | disclosed |
| EP-4313151-A1 | SOS1 INHIBITORS AND RAS INHIBITORS FOR USE IN THE TREATMENT OF PAIN | Sevenless Therapeutics Limited (GB) | 2024-02-07 | — | — | EP | disclosed |
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-12-05 | — | — | US | disclosed |
| EP-4121064-A1 | SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS | Glycologix, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022216294-A1 | POWDER FOR ORAL SUSPENSION CONTAINING TADALAFIL | AUSON PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022207673-A1 | SOS1 INHIBITORS AND RAS INHIBITORS FOR USE IN THE TREATMENT OF PAIN | SEVENLESS THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | WO | disclosed |
| WO-2002030470-A1 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | JOHNS HOPKINS UNIVERSITY (US) | 2002-04-18 | — | — | WO | disclosed |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002011706-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002011707-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | disclosed |
| EP-1113800-A1 | COMBINATIONS OF TETRACYCLIC CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS WITH FURTHER THERAPEUTIC AGENTS | ICOS CORPORATION (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015228-A1 | COMBINATIONS OF TETRACYCLIC CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS WITH FURTHER THERAPEUTIC AGENTS | ICOS CORPORATION (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834441-B2 | Substituted tetrahydrofurans as modulators of sodium channels | TRPV1, TRPA1, SCN2B | KDM4E 2978/4885ALDH1A1 1562/4885LMNA 3179/4885 |
| US-20020035111-A1 | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B] indole derivatives | MKI67, PNPO, CDK4 | KDM4E 1370/4885ALDH1A1 1323/4885LMNA 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.